Literature DB >> 19382171

Josephin domain of ataxin-3 contains two distinct ubiquitin-binding sites.

Giuseppe Nicastro1, Laura Masino, Veronica Esposito, Rajesh P Menon, Alfonso De Simone, Franca Fraternali, Annalisa Pastore.   

Abstract

Joseph-Machado is an incurable neurodegenerative disease caused by toxic aggregation of ataxin-3, a ubiquitin-specific cysteine protease, involved in the ubiquitin-proteasome pathway and known to bind poly-ubiquitin chains of four or more subunits. The enzymatic site resides in the N-terminal josephin domain of ataxin-3. We have characterized the ubiquitin-binding properties of josephin and showed that, unexpectedly, josephin contains two contiguous but distinct ubiquitin-binding sites. One is close to the enzymatic cleft and exploits an induced fit mechanism, which involves a flexible helical hairpin; the other overlaps with the site involved in recognition of HHR23B, a protein involved in delivering proteolytic substrates to the proteasome. To gain a structural description of the system, we had to overcome the nontrivial problem of dealing with a weak ternary complex. This was done by designing josephin mutants, which retain only one binding site and by characterizing the complexes with complementary computational and experimental techniques. The presence of two ubiquitin-binding sites explains how ataxin-3 binds poly-ubiquitin chains and provides new insights into the molecular mechanism of ubiquitin recognition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19382171     DOI: 10.1002/bip.21210

Source DB:  PubMed          Journal:  Biopolymers        ISSN: 0006-3525            Impact factor:   2.505


  42 in total

Review 1.  Toward understanding Machado-Joseph disease.

Authors:  Maria do Carmo Costa; Henry L Paulson
Journal:  Prog Neurobiol       Date:  2011-11-23       Impact factor: 11.685

2.  Interaction of the polyglutamine protein ataxin-3 with Rad23 regulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3.

Authors:  Joanna R Sutton; Jessica R Blount; Kozeta Libohova; Wei-Ling Tsou; Gnanada S Joshi; Henry L Paulson; Maria do Carmo Costa; K Matthew Scaglione; Sokol V Todi
Journal:  Hum Mol Genet       Date:  2017-04-15       Impact factor: 6.150

Review 3.  Breaking the chains: structure and function of the deubiquitinases.

Authors:  David Komander; Michael J Clague; Sylvie Urbé
Journal:  Nat Rev Mol Cell Biol       Date:  2009-08       Impact factor: 94.444

4.  Ataxin-3 expression correlates with the clinicopathologic features of gastric cancer.

Authors:  Li-Xia Zeng; Yong Tang; Yun Ma
Journal:  Int J Clin Exp Med       Date:  2014-04-15

5.  The deubiquitinase ataxin-3 requires Rad23 and DnaJ-1 for its neuroprotective role in Drosophila melanogaster.

Authors:  Wei-Ling Tsou; Michelle Ouyang; Ryan R Hosking; Joanna R Sutton; Jessica R Blount; Aaron A Burr; Sokol V Todi
Journal:  Neurobiol Dis       Date:  2015-05-22       Impact factor: 5.996

6.  Small heat-shock proteins interact with a flanking domain to suppress polyglutamine aggregation.

Authors:  Amy L Robertson; Stephen J Headey; Helen M Saunders; Heath Ecroyd; Martin J Scanlon; John A Carver; Stephen P Bottomley
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-19       Impact factor: 11.205

7.  Ubiquitin-binding site 2 of ataxin-3 prevents its proteasomal degradation by interacting with Rad23.

Authors:  Jessica R Blount; Wei-Ling Tsou; Gorica Ristic; Aaron A Burr; Michelle Ouyang; Holland Galante; K Matthew Scaglione; Sokol V Todi
Journal:  Nat Commun       Date:  2014-08-21       Impact factor: 14.919

Review 8.  Balancing act: deubiquitinating enzymes in the nervous system.

Authors:  Sokol V Todi; Henry L Paulson
Journal:  Trends Neurosci       Date:  2011-06-24       Impact factor: 13.837

9.  Understanding the role of the Josephin domain in the PolyUb binding and cleavage properties of ataxin-3.

Authors:  Giuseppe Nicastro; Sokol V Todi; Ezgi Karaca; Alexandre M J J Bonvin; Henry L Paulson; Annalisa Pastore
Journal:  PLoS One       Date:  2010-08-26       Impact factor: 3.240

10.  Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3.

Authors:  Fiona M Menzies; Jeannette Huebener; Maurizio Renna; Michael Bonin; Olaf Riess; David C Rubinsztein
Journal:  Brain       Date:  2009-12-09       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.